Companies /Healthcare

Agilent Technologies Inc

NYSE: A Diagnostics & Research
$157.88
â–² $2.80 (+1.80%) today
Markets open · 12:51pm ET

Q1 2026 Earnings

Reported Feb 25, 2026, 4:06pm ET · SEC source
$1.36
Miss −0.61%
EPS · est. $1.37
$1.8B
Miss −0.55%
Revenue · est. $1.8B
+0.9%
Beating market
A vs S&P since report
2 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−6%−3%0Feb 25Feb 26report 4:06pm ETearnings−0.6%−1.7%
−6%−3%0Feb 25Feb 26earnings−0.6%−1.7%
A −1.7%S&P 500 −0.6%
−6%−3%0Feb 25Feb 26report 4:06pm ETearnings−1.3%−1.7%
−6%−3%0Feb 25Feb 26earnings−1.3%−1.7%
A −1.7%NASDAQ −1.3%
−3%0+3%Feb 24Mar 5report 4:06pm ETearnings−2.1%−1.4%
−3%0+3%Feb 24Mar 5earnings−2.1%−1.4%
A −1.4%S&P 500 −2.1%
−3%0+3%Feb 24Mar 5report 4:06pm ETearnings−1.7%−1.4%
−3%0+3%Feb 24Mar 5earnings−1.7%−1.4%
A −1.4%NASDAQ −1.7%
−3.01%
Day of report
+0.34%
Next session
−2.36%
One week
−7.41%
30 days

S&P 500 over the same 30 days: −8.32%.

Did A Beat Earnings? Q1 2026 Results

Agilent Technologies narrowly missed Wall Street expectations in its fiscal first quarter of 2026, delivering non-GAAP EPS of $1.36 against a consensus of $1.37 and revenue of $1.80 billion versus an estimated $1.81 billion, though the company pointed to a major U.S. snowstorm in the final week of the quarter as the primary culprit behind the shortfall. Revenue still grew 7.0% year over year on a reported basis, with the Agilent CrossLab Group standing out as the quarter's brightest spot, posting 9% reported revenue growth to $758.00 million at a 31.6% operating margin. Operating cash flow fell sharply to $268.00 million from $431.00 million a year ago, reflecting higher employee compensation payouts and a surge in income tax payments to $105.00 million from just $19.00 million. Despite the modest misses, management raised its full-year fiscal 2026 revenue outlook to $7.30 billion to $7.50 billion and lifted non-GAAP EPS guidance to $5.90 to $6.04, citing favorable currency tailwinds, while institutional investors have continued building positions in the stock.

Key Takeaways
  • Continued momentum in instrument-replacement cycle
  • Strong engagement in Enterprise Services within Agilent CrossLab Group
  • Favorable currency impact contributing approximately 3 percentage points to reported revenue growth
  • Core revenue growth of 4.4% year-over-year
  • Ignite enterprise-wide operating system driving execution excellence and operational rigor

“It was a solid start to the year with the Agilent team executing well in a healthy — albeit dynamic — market environment that included navigating the impact of a major U.S. snowstorm during the last week of the quarter.”

Agilent Technologies CEO, on the earnings call

Forward Guidance & Outlook

For full fiscal year 2026, Agilent raised its revenue outlook to $7.3 billion–$7.5 billion, representing 5.5%–7.5% reported growth and 4%–6% core growth, while increasing non-GAAP EPS guidance to $5.90–$6.04 per share, reflecting favorable currency impacts. The company confirmed its core revenue growth and margin expansion targets for the year. For the fiscal second quarter 2026, revenue is expected in the range of $1.79 billion–$1.82 billion (approximately 7%–9% reported growth, 4%–5.5% core growth), with non-GAAP EPS of $1.39–$1.42 per share. The outlook is based on forecasted currency exchange rates.

A YoY Financials

Q1 2026 vs Q1 2025 · SEC filings Q1 2025 Q1 2026
$0$500.0M$1.0B$1.5B$1.7B$1.8BRevenue$899.0M$946.0MGross Profit$376.0M$353.0MOperating Income$318.0M$305.0MNet Income
$0$500.0M$1.0B$1.5BRevenueGross ProfitOperating IncomeNet Income

A Revenue by Segment

Agilent CrossLab Group$758.0M+9.0%
Life Sciences and Diagnostics Markets Group$679.0M+5.0%
Applied Markets Group$361.0M+7.0%

Figures from SEC filings and company reports. Not investment advice.